CT-FFR in Coronary Artery Disease: What the New SCCT/SCAI Consensus Means for Practice

Overview

Coronary CT angiography (CCTA) has emerged as the leading noninvasive modality for coronary artery disease (CAD) assessment, and the addition of CT-derived fractional flow reserve (CT-FFR) now enables simultaneous evaluation of both anatomical stenosis and lesion-specific ischemia from a single scan.

A landmark joint expert consensus document from the Society of Cardiovascular Computed Tomography (SCCT) and the Society for Cardiovascular Angiography and Interventions (SCAI), endorsed by the American College of Cardiology (ACC), was published in June 2026 in the Journal of Cardiovascular Computed Tomography to standardize acquisition, interpretation, and reporting of CT-FFR.

The core message is clear: CT-FFR should only be ordered when its result will actually change clinical management — layering tests that won't alter decision-making adds cost and noise without benefit.

CT-FFR using on-site machine learning identifies both the presence of CAD and vessel-specific ischemia, with diagnostic accuracy now considered comparable to invasive FFR.

The technology received FDA approval in 2022 via the HeartFlow computational fluid dynamics model, and the market now includes multiple competing platforms including HeartFlow and Keya Medical.

Guideline Context

Current US chest pain guidelines give CT-FFR a Class 2a (Level of Evidence B) recommendation for diagnosing vessel-specific ischemia or guiding clinical decisions when CCTA is inconclusive or shows a stenosis.

The European Society of Cardiology (ESC) chronic coronary syndrome guidelines carry a Class 2b (Level of Evidence B) recommendation for CT-FFR in patients with intermediate coronary lesions on CCTA.

The new consensus seeks to resolve variability in interpretation and reporting that has grown alongside increasing clinical adoption and a proliferating vendor landscape.

Key Recommendations

High-quality CCTA acquisition is non-negotiable — motion artifacts are the most common cause of failed CT-FFR analyses, and the consensus strongly recommends nitroglycerin and heart rate control during CCTA to optimize image quality.

The consensus recommends CT-FFR for stable chest pain and for lesions with diameter stenosis between 50% and 90% — the sweet spot where anatomy alone is most likely to be insufficient for clinical decision-making.

One of the most critical and potentially controversial recommendations is that post-lesional CT-FFR values must be reported at 2 cm distal to the stenosis rather than at the most distal point of the vessel, as distal measurements generate significantly more false positives and lower overall accuracy.

The document also integrates anatomical and physiological data, noting that the lesion location, scan quality, and CT-FFR value must always be interpreted together — not in isolation.

CT-FFR is deemed "reasonable" in acute chest pain, and "might be reasonable" during TAVI workup, preoperative CAD assessment in asymptomatic patients, and evaluation of three-vessel obstructive disease.

Clinical Utility & Evidence

In the multicenter PLATFORM study, CCTA ± CT-FFR led to delayed invasive coronary angiography (ICA) in 61% of cases, and significantly fewer patients had non-obstructive disease at ICA (12% vs. 73%, p=0.0001), underscoring CT-FFR's gatekeeper role.

Deep-learning CT-FFR in a pooled analysis of 2,566 CAD patients followed for at least 5 years showed modest but meaningful improvement in prediction of major adverse cardiovascular events (MACE) over anatomy-based models alone.

Both machine learning and computational fluid dynamics-based CT-FFR platforms demonstrate comparable diagnostic performance per a 2025 meta-analysis, offering clinicians greater flexibility in platform selection.

CT-FFR is most powerful in single- or dual-vessel epicardial disease; its utility diminishes in patients with prior stents or bypass grafts, where functional stress imaging (e.g., stress MRI) remains complementary and often superior.

Microvascular disease assessment remains outside CT-FFR's scope — perfusion-based modalities provide both epicardial and microvascular data and are more robust in anatomically challenging cases.

Practical Considerations

Clinical Scenario	CT-FFR Utility	Recommendation Level
Stable chest pain, 50–90% stenosis on CCTA	Highest — guides revascularization vs. medical therapy	Recommended
Acute chest pain	Emerging evidence; growing prospective data needed	Reasonable
TAVI workup / preoperative CAD assessment	Useful in asymptomatic patients; limited prospective data	Might be reasonable
Three-vessel obstructive CAD	Complex; lesion-by-lesion assessment may guide PCI planning	Might be reasonable
Post-stent or CABG patients	Limited — anatomy precludes reliable fluid dynamic modeling	Not recommended
Suspected microvascular disease	CT-FFR does not assess microvasculature; use perfusion imaging	Not applicable

Cost remains a significant barrier — CT-FFR is expensive, though still less costly than a diagnostic coronary angiography that does not result in percutaneous coronary intervention (PCI).

Increased market competition between vendors is expected to drive prices down, potentially improving cost-effectiveness and broadening access.

The consensus emphasizes that reporting standardization — including uniform formatting and consistent inclusion of post-lesional values — is as important as acquisition quality for clinical utility.

Open Questions & Future Directions

Prospective studies are needed for CT-FFR in acute chest pain, coronary allograft vasculopathy, TAVI workup, and preoperative evaluation of asymptomatic patients.

Cost reduction through vendor competition and expanding reimbursement pathways are prerequisites for CT-FFR to fulfill its full potential as an equitable, widely accessible diagnostic tool.

📋 Typical Case Scenario

A 58-year-old man with hypertension, hyperlipidemia, and exertional chest pain undergoes CCTA, which reveals a 65% stenosis of the mid-LAD. Anatomy alone is ambiguous — is this lesion hemodynamically significant? Rather than proceeding directly to invasive angiography, CT-FFR is added: the post-stenotic value at 2 cm distal to the lesion is 0.74 (≤0.80 = ischemia-inducing). With objective physiological confirmation of ischemia, the clinician confidently refers for PCI, bypassing an additional diagnostic catheterization. Result: one procedure instead of two, reduced radiation exposure, and a more confident shared decision with the patient.

References

1. Weir-McCall JR, Koweek L, Suchá D, et al. Fractional flow reserve in coronary computed tomography angiography: An expert consensus document of the SCCT and SCAI. Endorsed by the ACC. J Cardiovasc Comput Tomogr. 2026. DOI: 10.1016/j.jcct.2026.05.006
2. Chan C, Wang M, et al. Clinical applications of fractional flow reserve derived from computed tomography in coronary artery disease. Mayo Clin Proc Digit Health. 2024. PMC11975968
3. TARGET Trial. On-site CT-derived FFR to guide management of stable CAD. Circulation. AHA Journals
4. Prognostic significance of CT-FFR for long-term outcomes in CAD. J Am Heart Assoc. 2024. JAHA.124.037988
5. Candilio L. Fractional flow reserve from coronary CT: evidence, applications, and future directions. J Cardiovasc Dev Dis. 2025. PMC12386757